Progressive multiple sclerosis: from pathogenic mechanisms to treatment

Brain

Volumn 140, Issue 3, 2017, Pages 527-546

  Correale, Jorge ^a   Gaitán, María I ^a   Ysrraelit, María C ^a   Fiol, Marcela P ^a  

^a Instituto de Investigaciones Neurologicas Raul Carrera   (Argentina)

Author keywords

Axonal loss; Multiple sclerosis; Neurodegeneration; Primary progressive multiple sclerosis; Secondary progressive multiple sclerosis

Indexed keywords

6 NITRO 7 SULFAMOYLBENZO[F]QUINOXALINE 2,3 DIONE; BETA INTERFERON; BIOTIN; GLATIRAMER; GLUTAMIC ACID; IBUDILAST; ION CHANNEL; LAQUINIMOD; MASITINIB; MN 166; NEUROTROPHIN;

BRAIN ATROPHY; CLINICAL TRIAL; DEMYELINATION; ENCEPHALITIS; EXCITOTOXICITY; HISTOPATHOLOGY; HUMAN; IMMUNITY; MITOCHONDRION; MULTIPLE SCLEROSIS; NERVE DEGENERATION; NERVE FIBER DEGENERATION; NEUROPROTECTION; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; SPINAL CORD ATROPHY; DIAGNOSTIC IMAGING; DISEASE COURSE; IMMUNOLOGY; PATHOLOGY;

DISEASE PROGRESSION; HUMANS; MAGNETIC RESONANCE IMAGING; MULTIPLE SCLEROSIS;

EID: 85021847931     PISSN: 00068950     EISSN: 14602156     Source Type: Journal    
DOI: 10.1093/brain/aww258     Document Type: Review

References (186)

1. Absinta M, Sati P, Gaitan MI, Maggi P, Cortese IC, Filippi M, et al. Seven-tesla phase imaging of acute multiple sclerosis lesions: a new window into the inflammatory process. Ann Neurol 2013; 74: 669–78.
2. Absinta M, Vuolo L, Rao A, Nair G, Sati P, Cortese IC, et al. Gadolinium-based MRI characterization of leptomeningeal inflammation in multiple sclerosis. Neurology 2015; 85: 18–28.
3. Agosta F, Rovaris M, Pagani E, Sormani MP, Comi G, Filippi M. Magnetization transfer MRI metrics predict the accumulation of disability 8 years later in patients with multiple sclerosis. Brain 2006; 129 (Pt 10): 2620–7.
4. Al-Izki S, Pryce G, Hankey DJ, Lidster K, von Kutzleben SM, Browne L, et al. Lesional-targeting of neuroprotection to the inflammatory penumbra in experimental multiple sclerosis. Brain 2014; 137 (Pt 1): 92–108.
5. Aloisi F, Pujol-Borrell R. Lymphoid neogenesis in chronic inflammatory diseases. Nat Rev Immunol 2006; 6: 205–17.
6. Andersen O, Elovaara I, Färkkilä M, Hansen HJ, Mellgren SI, Myhr KM, et al. Multicentre, randomised, double blind, placebo controlled, phase III study of weekly, low dose, subcutaneous interferon beta-1a in secondary progressive multiple sclerosis. J Neurol Neurosurg Psychiatry 2004; 75:706–10.
7. Andersson PB, Waubant E, Gee L, Goodkin DE. Multiple sclerosis that is progressive from the time of onset: clinical characteristics and progression of disability. Ann Neurol 1999; 56: 1138–42.
8. Antel J, Antel S, Caramanos Z, Arnold DL, Kuhlmann T. Primary progressive multiple sclerosis: part of the MS disease spectrum or separate disease entity? Acta Neuropathol 2012; 123:627–38.
9. Antulov R, Weinstock-Guttman B, Cox JL, Hussein S, Durfee J, Caiola C, et al. Gender-related differences in MS: a study of conventional and nonconventional MRI measures. Mult Scler 2009; 15: 345–54.
10. Arnett HA, Mason J, Marino M, Suzuki K, Matsushima GK, Ting JP. TNF alpha promotes proliferation of oligodendrocyte progenitors and remyelination. Nat Neurosci 2001; 4: 1116–22.
11. Ascherio A, Munger KL. Epstein-barr virus infection and multiple sclerosis: a review. J Neuroimmune Pharmacol 2010; 5: 271–7.
12. Barnett MH, Prineas JW. Relapsing and remitting multiple sclerosis: pathology of the newly forming lesion. Ann Neurol 2004; 55: 458–68.
13. Bar-Or A, Fawaz L, Fan B, Darlington PJ, Rieger A, Ghorayeb C, et al. Abnormal B-cell cytokine responses a trigger of T-cell-mediated disease in MS? Ann Neurol 2010; 67: 452–61.
14. Bechtold DA, Kapoor R, Smith KJ. Axonal protection using flecainide in experimental autoimmune encephalomyelitis. Ann Neurol 2004; 55: 607–16.
15. Bechtold DA, Miller SJ, Dawson AC, Sun Y, Kapoor R, Berry D, et al. Axonal protection achieved in a model of multiple sclerosis using lamotrigine. J Neurol 2006; 253: 1542–51.
16. Bergendal G, Fredrikson S, Almkvist O. Selective decline in information processing in subgroups of multiple sclerosis: an 8-year longitudinal study. Eur Neurol 2007; 57:193–202.
17. Bitsch A, Schuchardt J, Bunkowski S, Kuhlmann T, Bruck W. Acute axonal injury in multiple sclerosis. Correlation with demyelination and inflammation. Brain 2000; 123 (Pt 6): 1174–83.
18. Black JA, Newcombe J, Trapp BD, Waxman SG. Sodium channel expression within chronic multiple sclerosis plaques. J Neuropathol Exp Neurol 2007; 66: 828–37.
19. Bo L, Vedeler CA, Nyland H, Trapp BD, Mork SJ. Intracortical multiple sclerosis lesions are not associated with increased lymphocyte infiltration. Mult Scler 2003a; 9: 323–31.
20. Bo L, Vedeler CA, Nyland HI, Trapp BD, Mork SJ. Subpial demyelination in the cerebral cortex of multiple sclerosis patients. J Neuropathol Exp Neurol 2003b; 62: 723–32.
21. Bonati U, Fisniku LK, Altmann DR, Yiannakas MC, Furby J, Thompson AJ, et al. Cervical cord and brain grey matter atrophy independently associate with long-term MS disability. J Neurol Neurosurg Psychiatry 2011; 82: 471–2.
22. Bramow S, Frischer JM, Lassmann H, Koch-Henriksen N, Lucchinetti CF, Sørensen PS, et al. Demyelination versus remyelination in progressive multiple sclerosis. Brain 2010; 133: 2983–98.
23. Bruck W, Pfortner R, Pham T, Zhang J, Hayardeny L, Piryatinsky V, et al. Reduced astrocytic NF-kappaB activation by laquinimod protects from cuprizone-induced demyelination. Acta Neuropathol 2012; 124: 411–24.
24. Buttmann M. Treating multiple sclerosis with monoclonal antibodies: a 2010 update. Expert Rev Neurother 2010; 10: 791–809.
25. Cadavid D, Keith E, Hupperts R, Drulovic J, Selmaj K, Naismith R, et al. BIIBo33, anti-LINGO treatment of relapsing-remitting Multiple Sclerosis: Basal data of the Phase 2 SYNERGY Trial. Neurology 2015; 84 (14 Suppl): P7204.
26. Cadavid D, Klistorner A, Leocani L, Aktas O, Butzkueven H, Ziemssen F, et al. Evidence that the Anti-Lingo-1 monoclonal antibody BIIBo33protects against multifocal visual evoked potential amplitud loss in the fellow eye of subjects with unilateral acute optic neuritis. Neurology 2016; 86 (16 Suppl): I10.009.
27. Camp SJ, Stevenson VL, Thompson AJ, Miller DH, Borras C, Auriacombe S, et al. Cognitive function in primary progressive and transitional progressive multiple sclerosis. A controlled study with MRI correlates. Brain 1999; 122:1341–8.
28. Campbell GR, Worrall JT, Mahad DJ. The central role of mitochondria in axonal degeneration in multiple sclerosis. Mult Scler 2014; 20: 1806–13.
29. Campbell GR, Ziabreva I, Reeve AK, Krishnan KJ, Reynolds R, Howell O, et al. Mitochondrial DNA deletions and neurodegeneration in multiple sclerosis. Ann Neurol 2011; 69: 481–92.
30. Caruso A, DiGiorgi Gerevini V, Castiglione M, Marinelli F, Tomassini V, Pozzilli C, et al. Testosterone amplifies excitotoxic damage of cultured oligodendrocytes. Neurochem 2004; 88: 1179–85.
31. Castillo-Trivino T, Braithwaite D, Bacchetti P, Waubant E. Rituximab in relapsing and progressive forms of multiple sclerosis: a systematic review. PloS One 2013; 8: e66308.
32. Choi SR, Howell OW, Carassiti D, Magliozzi R, Gveric D, Muraro PA, et al. Meningeal inflammation plays a role in the pathology of primary progressive multiple sclerosis. Brain 2012; 135 (Pt 10): 2925–37.
33. Ciric B, Van Keulen V, Paz Soldan M, Rodriguez M, Pease LR. Antibody-mediated remyelination operates through mechanism independent of immunomodulation. J Neuroimmunol 2004; 146: 153–61.
34. Cohen JA, Cutter GR, Fischer JS, Goodman AD, Heidenreich FR, Kooijmans MF, et al. Benefit of interferon beta-1a on MSFC progression in secondary progressive MS. Neurology 2002; 59: 679–87.
35. Cohen JA, Rudick RA. Multiple Sclerosis Therapeutics. Cambridge: Cambridge University Press; 2011.
36. Confavreux C, Vukusic S. Natural history of multiple sclerosis: a unifying concept. Brain 2006; 129 (Pt 3): 606–16.
37. Correale J. The role of microglial activation in disease progression. Mult Scler 2014; 20: 1288–95.
38. Correale J, Farez MF. The role of astrocytes in multiple sclerosis progression. Front Neurol 2015; 6: 180.
39. Corsiero E, Bombardieri M, Manzo A, Bugatti S, Uguccioni M, Pitzalis C. Role of lymphoid chemokines in the development of functional ectopic lymphoid structures in rheumatic autoimmune diseases. Immunol Lett 2012; 145: 62–7.
40. Cottrell DA, Kremenchutzky M, Rice GP, Koopman WJ, Hader W, Baskerville J, et al. The natural history of multiple sclerosis: a geographically based study. 5. The clinical features and natural history of primary progressive multiple sclerosis. Brain 1999; 122 (Pt 4): 625–39.
41. Cutter WJ, Daly EM, Robertson DM, Chitnis XA, van Amelsvoort TA, Simmons A,et al. Influence of X chromosome and hormones on human brain development: a magnetic resonance imaging and proton magnetic resonance spectroscopy study of Turner syndrome. Biol Psychiatry 2006; 59: 273–83.
42. Davies AL, Desai RA, Bloomfield PS, McIntosh PR, Chapple KJ, Linington C, et al. Neurological deficits caused by tissue hypoxia in neuroinflammatory disease. Ann Neurol 2013; 74: 815–25.
43. De Groot CJ, Bergers E, Kamphorst W, Ravid R, Polman CH, Barkhof F, et al. Post-mortem MRI-guided sampling of multiple sclerosis brain lesions: increased yield of active demyelinating and (p)reactive lesions. Brain 2001; 124 (Pt 8): 1635–45.
44. De Stefano N, Giorgio A, Battaglini M, Rovaris M, Sormani MP, Barkhof F, et al. Assessing brain atrophy rates in a large population of untreated multiple sclerosis subtypes. Neurology 2010; 74: 1868–76.
45. Di Pardo A, Amico E, Favellato M, Castrataro R, Fucile S, Squitieri F, et al. FTY720 (fingolimod) is a neuroprotective and disease-modifying agent in cellular and mouse models of Huntington disease. Hum Mol Genet 2014; 23: 2251–65.
46. Dubreuil P, Letard S, Ciufolini M, Gros L, Humbert M, Casteran N, et al. Masitinib (AB1010), a potent and selective tyrosine kinase inhibitor targeting KIT. PloS One 2009; 4: e7258.
47. Dutta R, Trapp BD. Pathogenesis of axonal and neuronal damage in multiple sclerosis. Neurology 2007; 68 (22 Suppl 3):S22–31
48. Dutta R, Trapp BD. Relapsing and progressive forms of multiple sclerosis: insights from pathology. Curr Opin Neurol 2014; 27: 271–8.
49. European Study Group on interferon-beta 1b in secondary porgressive MS. Placebo controlled multicenter randomized trial of interferon-beta 1b in treatment of secondary porgressive multiple sclerosis. Lancet 1998; 352:1491–97
50. Farez MF, Correale J. Sphingosine 1-phosphate signaling in astrocytes: implications for progressive multiple sclerosis. J Neurol Sci 2016; 361: 60–5.
51. Feng J, Misu T, Fujihara K, Sakoda S, Nakatsuji Y, Fukaura H, et al. Ibudilast, a nonselective phosphodiesterase inhibitor, regulates Th1/ Th2 balance and NKT cell subset in multiple sclerosis. Mult Scler 2004; 10: 494–8.
52. Filippi M, Campi A, Martinelli V, Colombo B, Yousry T, Canal N, et al. Comparison of triple dose versus standard dose gadolinium-DTPA for detection of MRI enhancing lesions in patients with primary progressive multiple sclerosis. J Neurol Neurosurg Psychiatry 1995; 59: 540–4.
53. Filippi M, Cercignani M, Inglese M, Horsfield MA, Comi G. Diffusion tensor magnetic resonance imaging in multiple sclerosis. Neurology 2001; 56: 304–11.
54. Fischer MT, Wimmer I, Hoftberger R, Gerlach S, Haider L, Zrzavy T, et al. Disease-specific molecular events in cortical multiple sclerosis lesions. Brain 2013; 136(Pt 6): 1799–815.
55. Fisher E, Lee JC, Nakamura K, Rudick RA. Gray matter atrophy in multiple sclerosis: a longitudinal study. Ann Neurol 2008; 64: 255–65.
56. Fisniku LK, Chard DT, Jackson JS, Anderson VM, Altman DR, Miszkiel KA, et al. Gray matter atrophy is related to long-term disability in multiple sclerosis. Ann Neurol 2008; 64: 247–54.
57. Frank JA, Richert N, Lewis B, Bash C, Howard T, Civil R, et al. A pilot study of recombinant insulin-like growth factor-1 in seven multiple sderosis patients. Mult Scler 2002; 8: 24–9.
58. Friese MA, Craner MJ, Etzensperger R, Vergo S, Wemmie JA, Welsh MJ, et al. Acid-sensing ion channel-1 contributes to axonal degeneration in autoimmune inflammation of the central nervous system. Nat Med 2007; 13: 1483–9.
59. Friese MA, Schattling B, Fugger L. Mechanisms of neurodegeneration and axonal dysfunction in multiple sclerosis. Nat Rev Neurol 2014; 10: 225–38.
60. Frischer JM, Bramow S, Dal-Bianco A, Lucchinetti CF, Rauschka H, Schmidbauer M, et al. The relation between inflammation and neurodegeneration in multiple sclerosis brains. Brain 2009; 132(Pt 5): 1175–89.
61. Fu L, Matthews PM, De Stefano N, Worsley KJ, Narayanan S, Francis GS, et al. Imaging axonal damage of normal-appearing white matter in multiple sclerosis. Brain 1998; 121 (Pt 1): 103–13.
62. Geurts JJ, Barkhof F. Grey matter pathology in multiple sclerosis. Lancet Neurol 2008; 7: 841–51.
63. Geurts JJ, Bo L, Pouwels PJ, Castelijns JA, Polman CH, Barkhof F. Cortical lesions in multiple sclerosis: combined postmortem MR imaging and histopathology. AJNR Am J Neuroradiol 2005; 26: 572–7.
64. Geurts JJ, Roosendaal SD, Calabrese M, Ciccarelli O, Agosta F, Chard DT, et al. Consensus recommendations for MS cortical lesion scoring using double inversion recovery MRI. Neurology 2011; 76: 418–24.
65. Giuliani F, Goodyer CG, Antel JP, Yong VW. Vulnerability of human neurons to T cell-mediated cytotoxicity. J Immunol 2003; 171: 368–79.
66. Goodin DS, Arnason BG, Coyle PK, Frohman EM, Paty DW. The use of mitoxantrone (Novantrone) for the treatment of multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 2003; 61: 1332–8.
67. Grossman RI, Gonzalez-Scarano F, Atlas SW, Galetta S, Silberberg DH. Multiple sclerosis: gadolinium enhancement in MR imaging. Radiology 1986; 161: 721–5.
68. Haider L, Fischer MT, Frischer JM, Bauer J, Hoftberger R, Botond G, et al. Oxidative damage in multiple sclerosis lesions. Brain 2011; 134 (Pt 7): 1914–24.
69. Hametner S, Wimmer I, Haider L, Pfeifenbring S, Bruck W, Lassmann H. Iron and neurodegeneration in the multiple sclerosis brain. Ann Neurol 2013; 74: 848–61.
70. Harris JO, Frank JA, Patronas N, McFarlin DE, McFarland HF. Serial gadolinium-enhanced magnetic resonance imaging scans in patients with early, relapsing-remitting multiple sclerosis: implications for clinical trials and natural history. Ann Neurol 1991; 29: 548–55.
71. Harrison DM, Oh J, Roy S, Wood ET, Whetstone A, Seigo MA, et al. Thalamic lesions in multiple sclerosis by 7T MRI: clinical implications and relationship to cortical pathology. Mult Scler 2015; 21: 1139–50.
72. Hartung HP, Gonsette R, Konig N, Kwiecinski H, Guseo A, Morrissey SP, et al. Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trial. Lancet 2002; 360: 2018–25.
73. Hauser SL, Oksenberg JR. The neurobiology of multiple sclerosis: genes, inflammation, and neurodegeneration. Neuron 2006; 52: 61–76.
74. Hawker K, O’Connor P, Freedman MS, Calabresi PA, Antel J, Simon J, et al. Rituximab in patients with primary progressive multiple sclerosis: results of a randomized double-blind placebo-controlled multicenter trial. Ann Neurol 2009; 66: 460–71.
75. Hayton T, Furby J, Smith KJ, Altmann DR, Brenner R, Chataway J, et al. Longitudinal changes in magnetisation transfer ratio in secondary progressive multiple sclerosis: data from a randomised placebo controlled trial of lamotrigine. J Neurol 2012; 259: 505–14.
76. Hislop AD, Taylor GS, Sauce D, Rickinson AB. Cellular responses to viral infection in humans: lessons from Epstein-Barr virus. Annu Rev Immunol 2007; 25: 587–617.
77. Hochmeister S, Grundtner R, Bauer J, Engelhardt B, Lyck R, Gordon G, et al. Dysferlin is a new marker for leaky brain blood vessels in multiple sclerosis. J Neuropathol Exp Neurol 2006; 65: 855–65.
78. Hohlfeld R. Neurotrophic cross-talk between the nervous and immune systems: relevance for repair strategies in multiple sclerosis? J Neurol Sci 2008; 265: 93–6.
79. Howell OW, Reeves CA, Nicholas R, Carassiti D, Radotra B, Gentleman SM, et al. Meningeal inflammation is widespread and linked to cortical pathology in multiple sclerosis. Brain 2011; 134 (Pt 9): 2755–71.
80. Huse M, Quann EJ, Davis MM. Shouts, whispers and the kiss of death: directional secretion in T cells. Nat Immunol 2008; 9: 1105–11.
81. Hutchinson M. Neurodegeneration in multiple sclerosis is a process separate from inflammation: no. Mult Scler 2015; 21: 1628–31.
82. Inglese M, Oesingmann N, Casaccia P, Fleysher L. Progressive multiple sclerosis and gray matter pathology: an MRI perspective. Mt Sinai J Med 2011; 78: 258–67.
83. Kalinowska-Lyszczarz A, Losy J. The role of neurotrophins in multiple sclerosis-pathological and clinical implications. Int J Mol Sci 2012; 13: 13713–25.
84. Kantarci OH, Lebrun C, Siva A, Keegan MB, Azevedo CJ, Inglese M, et al. Primary progressive MS evolving from radiologically isolated syndrome. Ann Neurol 2016; 79: 288–94.
85. Kassmann CM, Lappe-Siefke C, Baes M, Brugger B, Mildner A, Werner HB, et al. Axonal loss and neuroinflammation caused by peroxisome-deficient oligodendrocytes. Nat Genet 2007; 39: 969–76.
86. Katz Sand I, Krieger S, Farrell C, Miller AE. Diagnostic uncertainty during the transition to secondary progressive multiple sclerosis. Mult Scler 2014; 20: 1654–7.
87. Kearney H, Altmann DR, Samson RS, Yiannakas MC, Wheeler-Kingshott CA, Ciccarelli O, et al. Cervical cord lesion load is associated with disability independently from atrophy in MS. Neurology 2015; 84: 367–73.
88. Killestein J, Rudick RA, Polman CH. Oral treatment for multiple sclerosis. Lancet Neurol 2011; 10: 1026–34.
89. Kornek B Storch MK, Weissert R, Wallstroem E, Stefferl A, Olsson T, et al. Multiple sclerosis and chronic autoimmune encephalomyelitis: a comparative quantitative study of axonal injury in active, inactive, and remyelinated lesions. Am J Pathol 2000; 157: 267–76.
90. Kotter MR, Setzu A, Sim FJ, Van Rooijen N, Franklin RJ. Macrophage depletion impairs oligodendrocyte remyelination following lysolecithin-induced demyelination. Glia 2001; 35: 204–12.
91. Kremenchutzky M, Cottrell D, Rice G, Hader W, Baskerville J, Koopman W, et al. The natural history of multiple sclerosis: a geographically based study. 7. Progressive-relapsing and relapsing-progressive multiple sclerosis: a re-evaluation. Brain 1999; 122 (Pt 10): 1941–50.
92. Kremenchutzky M, Rice GP, Baskerville J, Wingerchuk DM, Ebers GC. The natural history of multiple sclerosis: a geographically based study 9: observations on the progressive phase of the disease. Brain 2006; 129 (Pt 3): 584–94.
93. Kuenz B, Lutterotti A, Ehling R, Gneiss C, Haemmerle M, Rainer C, et al. Cerebrospinal fluid B cells correlate with early brain inflammation in multiple sclerosis. PloS One 2008; 3: e2559.
94. Kutzelnigg A, Lucchinetti CF, Stadelmann C, Bruck W, Rauschka H, Bergmann M, et al. Cortical demyelination and diffuse white matter injury in multiple sclerosis. Brain 2005; 128 (Pt 11): 2705–12.
95. Lassmann H. Multiple sclerosis: lessons from molecular neuropathology. Exp Neurol 2014; 262 (Pt A): 2–7.
96. Lassmann H, Bruck W, Lucchinetti CF. The immunopathology of multiple sclerosis: an overview. Brain Pathol 2007; 17: 210–8.
97. Leary SM, Miller DH, Stevenson VL, Brex PA, Chard DT, Thompson AJ. Interferon beta-1a in primary progressive MS: an exploratory, randomized, controlled trial. Neurology 2003; 60: 44–51.
98. Louapre C, Lubetzki C. Neurodegeneration in multiple sclerosis is a process separate from inflammation: yes. Mult Scler 2015; 21: 1626–8.
99. Lovato L, Willis SN, Rodig SJ, Caron T, Almendinger SE, Howell OW, et al. Related B cell clones populate the meninges and parenchyma of patients with multiple sclerosis. Brain 2011; 134 (Pt 2): 534–41.
100. Lublin F, Miller DH, Freedman MS, Cree BA, Wolinsky JS, Weiner H, et al. Oral fingolimod in primary progressive multiple sclerosis (INFORMS): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet 2016; 387: 1075–84.
101. Lublin FD, Baier M, Cutter G. Effect of relapses on development of residual deficit in multiple sclerosis. Neurology 2003; 61: 1528–32.
102. Lublin FD, Reingold SC. Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis. Neurology 1996; 46: 907–11.
103. Lublin FD, Reingold SC, Cohen JA, Cutter GR, Sorensen PS, Thompson AJ, et al. Defining the clinical course of multiple sclerosis: the 2013 revisions. Neurology 2014; 83: 278–86.
104. Lucchinetti CF, Popescu BF, Bunyan RF, Moll NM, Roemer SF, Lassmann H, et al. Inflammatory cortical demyelination in early multiple sclerosis. N Engl J Med 2011; 365:2188–97.
105. Lugaresi A, Caporale C, Farina D, Marzoli F, Bonanni L, Muraro PA, et al. Low-dose oral methotrexate treatment in chronic progressive multiple sclerosis. Neurol Sci 2001; 22: 209–10.
106. Lycklama G, Thompson A, Filippi M, Miller D, Polman C, Fazekas F, et al. Spinal-cord MRI in multiple sclerosis. Lancet Neurol 2003; 2: 555–62.
107. Magliozzi R, Howell O, Vora A, Serafini B, Nicholas R, Puopolo M, et al. Meningeal B-cell follicles in secondary progressive multiple sclerosis associate with early onset of disease and severe cortical pathology. Brain 2007; 130 (Pt 4): 1089–104.
108. Magliozzi R, Howell OW, Reeves C, Roncaroli F, Nicholas R, Serafini B, et al. A Gradient of neuronal loss and meningeal inflammation in multiple sclerosis. Ann Neurol 2010; 68: 477–93.
109. Magliozzi R, Serafini B, Rosicarelli B, Chiappetta G, Veroni C, Reynolds R, et al. B-cell enrichment and Epstein-Barr virus infection in inflammatory cortical lesions in secondary progressive multiple sclerosis. J Neuropathol Exp Neurol 2013; 72: 29–41.
110. Mahad DJ, Ziabreva I, Campbell G, Lax N, White K, Hanson PS, et al. Mitochondrial changes within axons in multiple sclerosis. Brain 2009; 132 (Pt 5): 1161–74.
111. Mainero C, Louapre C, Govindarajan ST, Gianni C, Nielsen AS, Cohen-Adad J, et al. A gradient in cortical pathology in multiple sclerosis by in vivo quantitative 7 T imaging. Brain 2015; 138(Pt 4): 932–45.
112. Marrie RA, Reider N, Cohen J, Stuve O, Trojano M, Cutter G, et al. A systematic review of the incidence and prevalence of cardiac, cere-brovascular, and peripheral vascular disease in multiple sclerosis. Mult Scler 2015; 21: 318–31.
113. Matute C, Sanchez-Gomez MV, Martinez-Millan L, Miledi R. Glutamate receptor-mediated toxicity in optic nerve oligodendrocytes. Proc Natl Acad Sci USA 1997; 94: 8830–5.
114. Mayo L, Trauger SA, Blain M, Nadeau M, Patel B, Alvarez JI, et al. Regulation of astrocyte activation by glycolipids drives chronic CNS inflammation. Nat Med 2014; 20: 1147–56.
115. McFarland HF, Martin R. Multiple sclerosis: a complicated picture of autoimmunity. Nat Immunol 2007; 8: 913–9.
116. Medana IM, Gallimore A, Oxenius A, Martinic MM, Wekerle H, Neumann H. MHC class I-restricted killing of neurons by virus-specific CD8+ T lymphocytes is effected through the Fas/FasL, but not the perforin pathway. Eur J Immunol 2000; 30: 3623–33.
117. Meuth SG, Herrmann AM, Simon OJ, Siffrin V, Melzer N, Bittner S, et al. Cytotoxic CD8 + T cell-neuron interactions: perforin-dependent electrical silencing precedes but is not causally linked to neuronal cell death. J Neurosci 2009; 29: 15397–409.
118. Meuth SG, Simon OJ, Grimm A, Melzer N, Herrmann AM, Spitzer P, et al. CNS inflammation and neuronal degeneration is aggravated by impaired CD200-CD200R-mediated macrophage silencing. J Neuroimmunol 2008; 194: 62–9.
119. Mi S, Hu B, Hahm K, Luo Y, Kam Hui ES, Yuan Q, et al. LINGO-1 antagonist promotes spinal cord remyelination and axonal integrity in MOG-induced experimental autoimmune encephalomyelitis. Nat Med 2007; 13: 1228–33.
120. Mishra MK, Wang J, Keough MB, Fan Y, Silva C, Sloka S, et al. Laquinimod reduces neuroaxonal injury through inhibiting microglial activation. Ann Clin Transl Neurol 2014; 1: 409–22.
121. Mitsunaga Y, Ciric B, Van Keulen V, Warrington AE, Paz Soldan M, Bieber AJ, et al. Direct evidence that a human antibody derived from patient serum can promote myelin repair in a mouse model of chronic-progressive demyelinating disease. FASEB J 2002; 16: 1325–7.
122. Mizuno T, Zhang G, Takeuchi H, Kawanokuchi J, Wang J, Sonobe Y, et al. Interferon-gamma directly induces neurotoxicity through a neuron specific, calcium-permeable complex of IFN-gamma receptor and AMPA GluR1 receptor. FASEB J 2008; 22: 1797–806.
123. Moll NM, Rietsch AM, Thomas S, Ransohoff AJ, Lee JC, Fox R, et al. Multiple sclerosis normal-appearing white matter: pathology-imaging correlations. Ann Neurol 2011; 70: 764–73.
124. Montalban X, Sastre-Garriga J, Tintore M, Brieva L, Aymerich FX, Rio J, et al. A single-center, randomized, double-blind, placebo-controlled study of interferon beta-1b on primary progressive and transitional multiple sclerosis. Mult Scler 2009; 15: 1195–205.
125. Murphy MP. How mitochondria produce reactive oxygen species. Biochem J 2009; 417: 1–13.
126. Nicholls DG. Mitochondrial dysfunction and glutamate excitotoxicity studied in primary neuronal cultures. Curr Mol Med 2004; 4: 149–77.
127. Nielsen AS, Kinkel RP, Madigan N, Tinelli E, Benner T, Mainero C. Contribution of cortical lesion subtypes at 7T MRI to physical and cognitive performance in MS. Neurology 2013; 81: 641–9.
128. Nikic I, Merkler D, Sorbara C, Brinkoetter M, Kreutzfeldt M, Bareyre FM, et al. A reversible form of axon damage in experimental autoimmune encephalomyelitis and multiple sclerosis. Nat Med 2011; 17: 495–9.
129. Ontaneda D, Fox RJ, Chataway J. Clinical trials in progressive multiple sclerosis: lessons learned and future perspectives. Lancet Neurol 2015; 14: 208–23.
130. Ouardouz M, Coderre E, Basak A, Chen A, Zamponi GW, Hameed S, et al. Glutamate receptors on myelinated spinal cord axons: I. GluR6 kainate receptors. Ann Neurol 2009; 65: 151–9.
131. Pagani E, Rocca MA, Gallo A, Rovaris M, Martinelli V, Comi G, et al. Regional brain atrophy evolves differently in patients with multiple sclerosis according to clinical phenotype. AJNR Am J Neuroradiol 2005; 26: 341–6.
132. Panitch H, Miller A, Paty D, Weinshenker B; North American Study Group onInterferon beta-1b in Secondary Progressive MS. Interferon beta-1b in secondary progressive MS: results from a 3-year controlled study. Neurology 2004; 63:1788–95.
133. Paolillo A, Coles AJ, Molyneux PD, Gawne-Cain M, MacManus D, Barker GJ, et al. Quantitative MRI in patients with secondary progressive MS treated with monoclonal antibody Campath 1H. Neurology 1999; 53: 751–7.
134. Pardridge WM. Neurotrophins, neuroprotection and the blood-brain barrier. Curr Opin Investig Drugs 2002; 3: 1753–7.
135. Peterson JW, Bo L, Mork S, Chang A, Trapp BD. Transected neurites, apoptotic neurons, and reduced inflammation in cortical multiple sclerosis lesions. Ann Neurol 2001; 50: 389–400.
136. Pitt D, Boster A, Pei W, Wohleb E, Jasne A, Zachariah CR, et al. Imaging cortical lesions in multiple sclerosis with ultra-high-field magnetic resonance imaging. Arch Neurol 2010; 67: 812–8.
137. Pitt D, Werner P, Raine CS. Glutamate excitotoxicity in a model of multiple sclerosis. Nat Med 2000; 6: 67–70.
138. Polman CH, Reingold SC, Banwell B, Clanet M, Cohen JA, Filippi M, et al. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol 2011; 69: 292–302.
139. Popescu BF, Lucchinetti CF. Meningeal and cortical grey matter pathology in multiple sclerosis. BMC Neurol 2012; 12: 11.
140. Pradat PF, Kennel P, Naimi-Sadaoui S, Finiels F, Orsini C, Revah F, et al. Continuous delivery of neurotrophin 3 by gene therapy has a neuroprotective effect in experimental models of diabetic and acryl-amide neuropathies. Hum Gene Ther 2001; 12: 2237–49.
141. Preziosa P, Rocca MA, Mesaros S, Pagani E, Stosic-Opincal T, Kacar K, et al. Intrinsic damage to the major white matter tracts in patients with different clinical phenotypes of multiple sclerosis: a voxelwise diffusion-tensor MR study. Radiology 2011; 260: 541–50.
142. Rice CM, Cottrell D, Wilkins A, Scolding NJ. Primary progressive multiple sclerosis: progress and challenges. J Neurol Neurosurg Psychiatry 2013; 84: 1100–6.
143. Revesz T, Kidd D, Thompson AJ, Barnard RO, McDonald WI. A comparison of the pathology of primary and secondary progressive multiple sclerosis. Brain 1994; 117 (Pt 4): 759–65.
144. Rossi S, Motta C, Studer V, Barbieri F, Buttari F, Bergami A, et al. Tumor necrosis factor is elevated in progressive multiple sclerosis and causes excitotoxic neurodegeneration. Mult Scler 2014; 20: 304–12.
145. Rovaris M, Confavreux C, Furlan R, Kappos L, Comi G, Filippi M. Secondary progressive multiple sclerosis: current knowledge and future challenges. Lancet Neurol 2006; 5: 343–54.
146. Sbardella E, Greco A, Stromillo ML, Prosperini L, Puopolo M, Cefaro LA, et al. Isoprostanes in clinically isolated syndrome and early multiple sclerosis as biomarkers of tissue damage and predictors of clinical course. Mult Scler 2013; 19: 411–7.
147. Scalfari A, Neuhaus A, Degenhardt A, Rice GP, Muraro PA, Daumer M, et al. The natural history of multiple sclerosis: a geographically based study 10: relapses and long-term disability. Brain 2010; 133 (Pt 7): 1914–29.
148. Schattling B, Steinbach K, Thies E, Kruse M, Menigoz A, Ufer F, et al. TRPM4 cation channel mediates axonal and neuronal degeneration in experimental autoimmune encephalomyelitis and multiple sclerosis. Nat Med 2012; 18: 1805–11.
149. Schlaeger R, Papinutto N, Panara V, Bevan C, Lobach IV, Bucci M, et al. Spinal cord gray matter atrophy correlates with multiple sclerosis disability. Ann Neurol 2014; 76: 568–80.
150. Schlaeger R, Papinutto N, Zhu AH, Lobach IV, Bevan CJ, Bucci M, et al. Association between thoracic spinal cord gray matter atrophy and disability in multiple sclerosis. JAMA Neurol 2015; 72: 897–904.
151. Schmierer K, Scaravilli F, Altmann DR, Barker GJ, Miller DH. Magnetization transfer ratio and myelin in postmortem multiple sclerosis brain. Ann Neurol 2004; 56: 407–15.
152. Schwartzman RJ, Simpkins N, Alexander GM, Reichenberger E, Ward K, Lindenberg N, et al. High-dose cyclophosphamide in the treatment of multiple sclerosis. CNS Neurosci Ther 2009; 15: 118–27.
153. Scolding N, Franklin R. Axon loss in multiple sclerosis. Lancet 1998; 352: 340–1.
154. Sedel F, Bernard D, Mock DM, Tourbah A. Targeting demyelination and virtual hypoxia with high-dose biotin as a treatment for progressive multiple sclerosis. Neuropharmacology 2015 Sep 5. doi:1016/j.neuropharm.2015.08.028 [Epub ahead of print].
155. Serafini B, Rosicarelli B, Magliozzi R, Stigliano E, Aloisi F. Detection of ectopic B-cell follicles with germinal centers in the meninges of patients with secondary progressive multiple sclerosis. Brain Pathol 2004; 14: 164–74.
156. Sethi V, Muhlert N, Ron M, Golay X, Wheeler-Kingshott CA, Miller DH, et al. MS cortical lesions on DIR: not quite what they seem? PloS One 2013; 8: e78879.
157. Silver NC, Tofts PS, Symms MR, Barker GJ, Thompson AJ, Miller DH. Quantitative contrast-enhanced magnetic resonance imaging to evaluate blood-brain barrier integrity in multiple sclerosis: a preliminary study. Mult Scler 2001; 7: 75–82.
158. Smith KJ, Kapoor R, Hall SM, Davies M. Electrically active axons degenerate when exposed to nitric oxide. Ann Neurol 2001; 49: 470–6.
159. Secondary Progressive Efficacy Clinical Trial of Recombinant Interferon-Beta-1a in MS (SPECTRIMS) Study Group. Randomized controlled trial of interferon- beta-1a in secondary progressive MS: clinical results. Neurology 2001; 56: 1496–504.
160. Stevenson VL, Miller DH, Rovaris M, Barkhof F, Brochet B, Dousset V, et al. Primary and transitional progressive MS: a clinical and MRI cross-sectional study. Neurology 1999; 52: 839–45.
161. Strassburger-Krogias K, Ellrichmann G, Krogias C, Altmeyer P, Chan A, Gold R. Fumarate treatment in progressive forms of multiple sclerosis: first results of a single-center observational study. Ther Adv Neurol Disord 2014; 7: 232–8.
162. Stys PK. General mechanisms of axonal damage and its prevention. J Neurol Sci 2005; 233: 3–13.
163. Suhy J, Rooney WD, Goodkin DE, Capizzano AA, Soher BJ, Maudsley AA, et al. 1H MRSI comparison of white matter and lesions in primary progressive and relapsing-remitting MS. Mult Scler 2000; 6: 148–55.
164. Suzumura A, Ito A, Mizuno T. Phosphodiesterase inhibitors suppress IL-12 production with microglia and T helper 1 development. Mult Scler 2003; 9: 574–8.
165. Tagge I, O’Connor A, Chaudhary P, Pollaro J, Berlow Y, Chalupsky M, et al. Spatio-temporal patterns of demyelination and remyelination in the cuprizone mouse model. PLoS One 2016; 11:e0152480
166. Thompson AJ, Kermode AG, MacManus DG, Kendall BE, Kingsley DP, Moseley IF, et al. Patterns of disease activity in multiple sclerosis: clinical and magnetic resonance imaging study. BMJ 1990a; 300: 631–4.
167. Thompson AJ, Miller DH, MacManus DG, McDonald WI. Patterns of disease activity in multiple sclerosis. BMJ 1990b; 301: 44–5.
168. Thompson AJ, Toosy AT, Ciccarelli O. Pharmacological management of symptoms in multiple sclerosis: current approaches and future directions. Lancet Neurol 2010; 9: 1182–99.
169. Tourbah A, Lebrun-Frenay C, Edan G, Clanet M, Papex C, Vukusic S, et al. 233 MD1003 (high doses of biotin) in progressive multiple sclerosis: subgroup analyses of the MS-SPI trial. Mult Scler J 2015; 21: (S11) 784.
170. Tourbah A, Lebrun-Frenay C, Edan G, Clanet M, Papex C, Vukusic S, et al. 24-Month-treatment with-MD1003 (high doses of Biotin) in progressive multiple sclerosis: results of the MS-SPI trial extension phase. Neurology 2016; 86: Suppl S49.004
171. Traboulsee A, Dehmeshki J, Peters KR, Griffin CM, Brex PA, Silver N, et al. Disability in multiple sclerosis is related to normal appearing brain tissue MTR histogram abnormalities. Mult Scler 2003; 9: 566–73.
172. Tran JQ, Rana J, Barkhof F, Melamed I, Gevorkyan H, Wattjes MP, et al. Randomized phase I trials of the safety/tolerability of anti-LINGO-1 monoclonal antibody BIIB033. Neurol Neuroimmunol Neuroinflamm 2014; 1: e18.
173. Trapp BD, Nave KA. Multiple sclerosis: an immune or neurodegenerative disorder? Annu Rev Neurosci 2008; 31: 247–69.
174. Trapp BD, Peterson J, Ransohoff RM, Rudick R, Mork S, Bo L. Axonal transection in the lesions of multiple sclerosis. N Engl J Med 1998; 338: 278–85.
175. Trapp BD, Stys PK. Virtual hypoxia and chronic necrosis of demyelinated axons in multiple sclerosis. Lancet Neurol 2009; 8: 280–91.
176. Ukkonen M, Vahvelainen T, Hämäläinen P, Dastidar P, Elovaara I. Cognitive dysfunction in primary progressive multiple sclerosis: a neuropsychological and MRI study. Mult Scler 2009; 15: 1055–61.
177. Venters HD, Dantzer R, Kelley KW. A new concept in neurodegeneration: TNFalpha is a silencer of survival signals. Trends Neurosci 2000; 23: 175–80.
178. Vercellino M, Masera S, Lorenzatti M, Condello C, Merola A, Mattioda A, et al. Demyelination, inflammation, and neurodegeneration in multiple sclerosis deep gray matter. J Neuropathol Exp Neurol 2009; 68: 489–502.
179. Vergo S, Craner MJ, Etzensperger R, Attfield K, Friese MA, Newcombe J, et al. Acid-sensing ion channel 1 is involved in both axonal injury and demyelination in multiple sclerosis and its animal model. Brain 2011; 134(Pt 2): 571–84.
180. Warner HB, Carp RI. Multiple sclerosis and Epstein-Barr virus. Lancet 1981; 2: 1290.
181. Waxman SG. Axonal conduction and injury in multiple sclerosis: the role of sodium channels. Nat Rev Neurosci 2006; 7: 932–41.
182. Wilkins A, Majed H, Layfield R, Compston A, Chandran S. Oligodendrocytes promote neuronal survival and axonal length by distinct intracellular mechanisms: a novel role for oligodendrocyte-derived glial cell line-derived neurotrophic factor. J Neurosci 2003; 23: 4967–74.
183. Willis SN, Stadelmann C, Rodig SJ, Caron T, Gattenloehner S, Mallozzi SS, et al. Epstein-Barr virus infection is not a characteristic feature of multiple sclerosis brain. Brain 2009; 132(Pt 12): 3318–28.
184. Wolinsky JS, Narayana PA, O’Connor P, Coyle PK, Ford C, Johnson K, et al. Glatiramer acetate in primary progressive multiple sclerosis: results of a multinational, multicenter, double-blind, placebo-controlled trial. Ann Neurol 2007; 61: 14–24.
185. Yong VW. Prospects of repair in multiple sclerosis. J Neurol Sci 2009; 277 (Suppl 1): S16–8.
186. Young EA, Fowler CD, Kidd GJ, Chang A, Rudick R, Fisher E, et al. Imaging correlates of decreased axonal Na + /K + ATPase in chronic multiple sclerosis lesions. Ann Neurol 2008; 63: 428–35.